Aligos Therapeutics (NASDAQ:ALGS) Announces Quarterly Earnings Results

Aligos Therapeutics (NASDAQ:ALGS) posted its quarterly earnings data on Wednesday. The company reported ($3.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92), Zacks reports. The firm had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.00 million. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same period in the prior year, the firm earned ($10.25) earnings per share.

Aligos Therapeutics Trading Up 2.7 %

Shares of ALGS stock traded up $0.27 during trading on Friday, hitting $10.19. The company’s stock had a trading volume of 108,249 shares, compared to its average volume of 39,795. The company has a market cap of $32.61 million, a PE ratio of -0.50 and a beta of 2.11. The business has a fifty day moving average of $9.81 and a 200-day moving average of $12.63. Aligos Therapeutics has a 52 week low of $6.76 and a 52 week high of $30.00.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Aligos Therapeutics in a report on Thursday.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).